Von Willebrand factor deficiency and atherosclerosis

Galen, Karin P M van; Tuinenburg, A.; Smeets, Emma M.; Schutgens, Roger E. G.

doi:10.1016/j.blre.2012.05.002

Cited by 47 publications

(50 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was associated with the increase in LDL and atherogenesis (van Galen et al, 2012).Our results confirmed these suggestions, we found elevation in LDL and vWF levels in OVX group. Our data revealed that in ovariectomized rats there was a significant decrease in erythrocyte membrane ALA along with increase in AA and LA compared to sham group.…”

Section: Discussionsupporting

confidence: 81%

New approaches in protecting against atherosclerosis in experimental model of postmenopause

2017

J App Pharm Sci

View full text Add to dashboard Cite

This work is aimed to evaluate the ability of Myrtus communis leaves extract in attenuating endothelial dysfunction as well as risk of atherosclerosis in ovariectomized rats as a common model of postmenopause. Total 60 female albino rats, weighing 180 g were used and assigned to four groups (sham, sham and Myrtus communis leaves extract, ovariectomized rats (OVX) and ovariectomized treated rats with Myrtus communis leaves extract). Plasma estrogen, lipid profile, asymmetric dimethylarginine (ADMA), von Willebrand factor (vWF), interleukin 1beta (IL-1β), Lipoxin A4 (LXA4), aortic oxidant and antioxidant in addition to erythrocyte membrane fatty acids were determined. OVX rats showed a significant increase in inflammatory and oxidant parameters while, Myrtus communis extract administration (100 mg/kg body weight) for two months attenuates these values in treated group. Myrtus communis leaves extract confirmed our idea in protecting from atherosclerosis and endothelial dysfunction in ovariectomized rats due to its high content of anti-oxidant and anti-inflammatory compounds in addition to its high content of ω-3 fatty acids.

show abstract

Section: Discussionsupporting

confidence: 81%

New approaches in protecting against atherosclerosis in experimental model of postmenopause

2017

J App Pharm Sci

View full text Add to dashboard Cite

show abstract

“…22,23 However, these markers might not be appropriate to assess other important processes linked to endothelial damage, such as adhesion and migration of leucocytes. Further studies should assess the role of cell adhesion molecules in the observed associations.…”

Section: Discussionmentioning

confidence: 99%

“…Both tPA and vWf are produced by endothelial cells and can be considered as markers of endothelial dysfunction. 22,23 It has been Figure 2 Multivariate-adjusted hazard ratio (HR) for one unit of increase in heart rate, according to gender, inflammatory markers levels, endothelial dysfunction, and statin use. HRs are adjusted for age, sex, smoking status, diabetes, history of cardiovascular disease, history of angina, hypertension, body mass index, HDL-cholesterol, thyroid-stimulating hormone, and glomerular filtration rate.…”

Section: Discussionmentioning

confidence: 99%

Resting heart rate and incident heart failure and cardiovascular mortality in older adults: role of inflammation and endothelial dysfunction: the PROSPER study

Nanchen

Stott

Gussekloo

et al. 2013

European J of Heart Fail

View full text Add to dashboard Cite

AimsResting heart rate is a promising modifiable cardiovascular risk marker in older adults, but the mechanisms linking heart rate to cardiovascular disease are not fully understood. We aimed to assess the association between resting heart rate and incident heart failure (HF) and cardiovascular mortality, and to examine whether these associations might be attributable to systemic inflammation and endothelial dysfunction. Methods and resultsWe studied 4084 older adults aged 70-82 years with known cardiovascular risk factors or previous cardiovascular disease, without pre-existing HF or beta-blockers in the PROSPER study. Over a 3.2-year follow-up period, we examined incident HF hospitalization and cardiovascular mortality according to resting heart rate, along with C-reactive protein (CRP), interleukin-6 (IL-6), tissue plasminogen activator (tPA), and von Willebrand factor (vWf). Mean heart rate was 67 b.p.m. for men and 70 b.p.m. for women. CRP, IL-6, tPA, and vWf levels were all positively correlated with heart rate. After multivariate adjustment, heart rate was associated with HF hospitalization [hazard ratio (HR) 1.78 for highest vs. lowest distribution third, 95% confidence interval (CI) 1.21-2.63, P ¼ 0.003] and cardiovascular mortality (HR 1.74, 95% CI 1.23-2.47, P ¼ 0.002). Further adjustment for both IL-6 and vWf levels decreased HR to 1.60 (95% CI 1.08-2.38, P ¼ 0.020) for HF and to 1.50 (95% CI 1.04-2.15, P ¼ 0.028) for cardiovascular mortality. ConclusionIncreased heart rate is associated with increased systemic inflammation and endothelial dysfunction. These factors are likely to contribute to, but do not fully explain, the risk of HF and cardiovascular death associated with increased heart rate in older age.--

show abstract

“…A large number of animal models have shown that VWF deficiency may have a protective effect against atherosclerosis and arterial thrombosis risk in both small and large arteries 58. Studies in humans have been less clear, however, with most trials showing only modest reductions in atherosclerosis 59–63.…”

Section: Vwd and Cardiovascular Eventsmentioning

confidence: 99%

Von Willebrand Disease in the elderly: clinical perspectives

Chapin

2018

CIA

View full text Add to dashboard Cite

Von Willebrand disease (VWD) is an inherited bleeding disorder that affects up to 1% of the population. In most cases, VWD results from a mutation in the von Willebrand Factor (VWF) gene, which alters the amount and function of VWF, a key glycoprotein in both primary and secondary hemostasis. A comprehensive analysis of patients with VWD should include VWF activity, antigen levels, platelet function, and a careful bleeding history. Treatment options include antifibrinolytics, desmopressin, and VWF replacement therapy. VWF levels fluctuate due to age, stress, environmental exposures, and pharmacologic treatment. Treatment guidelines exist to treat and prevent bleeding for patients undergoing surgery and medical procedures, but often these must be reevaluated in the setting of age-related comorbidities including cardiovascular events, venous thrombosis, and malignancy. In addition, many age-related complications are associated with a secondary acquired von Willebrand syndrome (AVWS), including malignancies, hypothyroidism, cardiovascular diseases, and cardiac replacement devices. The current literature is limited by a lack of older patients in clinical trials. Larger studies are needed to determine if age-related comorbidities affect VWD patients at different frequencies than the general elderly population. There is also a significant need for registry-based studies to evaluate many age-related comorbidities in VWD patients.

show abstract

Von Willebrand factor deficiency and atherosclerosis

Cited by 47 publications

References 61 publications

New approaches in protecting against atherosclerosis in experimental model of postmenopause

New approaches in protecting against atherosclerosis in experimental model of postmenopause

Resting heart rate and incident heart failure and cardiovascular mortality in older adults: role of inflammation and endothelial dysfunction: the PROSPER study

Von Willebrand Disease in the elderly: clinical perspectives

Contact Info

Product

Resources

About